Abstract
Transgenic mice expressing specific oncogenes usually develop tumors in a stochastic fashion suggesting that tumor progression is a multi-step process. To gain further understanding of the interactions between oncogenes and tumor suppressor genes during tumorigenesis, we have crossed a transgenic strain (TG.NK) carrying an activated c-neu oncogene driven by the MMTV enhancer/promoter with p53-deficient mice. c-neu transgenic mice have stochastic breast tumor formation and normal appearing salivary glands. However, c-neu mice heterozygous for a p53 deletion develop parotid gland tumors and loose their wild type p53 allele. c-neu mice with a homozygous p53 deletion have increased rates of parotid tumor onset suggesting that inactivation of p53 is required and sufficient for parotid gland transformation in the presence of activated c-neu. In contrast to the dramatic effect of p53 in parotid gland transformation, p53 loss has little effect on the rate or stochastic appearance of mammary tumors. In addition, p53 loss was accompanied by the down regulation of p21 in parotid gland tumors but not breast tumors. The parotid gland tumors were aneuploid and demonstrated increased levels of Cyclin D1 expression. These observations suggest that in c-neu transgenic mice, p53 alterations have differential tissue effects and may be influenced by the tissue specific expression of genes influencing p53 activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bargmann CI, Hung MC, Weinberg RA . 1986 Cell 45: 649–657
Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P . 1989 Cell 57: 931–936
Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ . 1995 Nature 377: 552–557
Califano J, Eisele DW . 1999 Otolaryngol. Clin. North Am. 32: 861–873
Cardiff RD, Sinn E, Muller W, Leder P . 1991 Am. J. Pathol. 139: 495–501
Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY . 1999 Oncogene 18: 7883–7899
Deng C, Zhang P, Harper JW, Elledge SJ, Leder P . 1995 Cell 82: 675–684
Donehower LA . 1997 Cancer Surv. 29: 329–352
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A . 1992 Nature 356: 215–221
Earp HS, Dawson TL, Li X, Yu H . 1995 Breast Cancer Res. Treat. 35: 115–132
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B . 1993 Cell 75: 817–825
Elson A, Deng C, Campos-Torres J, Donehower LA, Leder P . 1995 Oncogene 11: 181–190
Evans EP . 1987 In Monk, M. (ed.) Mammalian Development IRL Press Limited, Oxford pp. 93–114
Graus-Porta D, Beerli RR, Daly JM, Hynes NE . 1997 EMBO J. 16: 1647–1655
Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR . 1990 J. Pathol. 161: 195–200
Hand AR, Pathmanathan D, Field RB . 1999 Arch. Oral. Biol. 44: Suppl 1 S3–10
Harvey M, McArthur MJ, Montgomery Jr CA, Bradley A, Donehower LA . 1993 FASEB J. 7: 938–943
Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B . 1997 Mol. Cell. 1: 3–11
Hunter T . 1991 Cell 64: 249–270
Hynes NE . 1996 J. Mammary Gland Biol. Neoplasia 1: 199–206
Isola J, Chu L, DeVries S, Matsumura K, Chew K, Ljung BM, Waldman FM . 1999 Clin. Cancer Res. 5: 4140–4145
Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA . 1994 Curr. Biol. 4: 1–7
Jimenez RE, Wallis T, Tabasczka P, Visscher DW . 2000 Mod. Pathol. 13: 37–45
Kamio N . 1996 Virchows Arch. 428: 75–83
Knudson CM, Korsmeyer SJ . 1997 Nat. Genet. 16: 358–363
Knudson CM, Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ . 1995 Science 270: 96–99
Lee JM, Bernstein A . 1993 Proc. Natl. Acad. Sci. USA 90: 5742–5746
Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines III GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG . 2000 Mol. Cell. Biol. 20: 672–683
Levine AJ . 1997 Cell 88: 323–331
Linke SP, Clarkin KC, Wahl GM . 1997 Cancer Res. 57: 1171–1179
Lucchini F, Sacco MG, Hu N, Villa A, Brown J, Cesano L, Mangiarini L, Rindi G, Kindl S, Sessa F, Vezzoni P, Clerici L . 1992 Cancer Lett. 64: 203–209
Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J, Strong LC . 1992 N. Engl. J. Med. 326: 1309–1315
Menard S, Tagliabue E, Campiglio M, Pupa SM . 2000 J. Cell. Physiol. 182: 150–162
Morgan SE, Kastan MB . 1997 Adv. Cancer Res. 71: 1–25
Muller S, Vigneswaran N, Gansler T, Gramlich T, DeRose PB, Cohen C . 1994 Mod. Pathol. 7: 628–632
Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P . 1988 Cell 54: 105–115
Oswald F, Lovec H, Moroy T, Lipp M . 1994 Oncogene 9: 2029–2036
Pignataro L, Capaccio P, Carboni N, Pruneri G, Ottaviani A, Buffa R, Broich G . 1998 Anticancer Res. 18: 1287–1290
Pinkas-Kramarski R, Alroy I, Yarden Y . 1997 J. Mammary Gland Biol. Neoplasia 2: 97–107
Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y . 1996 J. Biol. Chem. 271: 19029–19032
Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B . 1997 Nature 389: 300–305
Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG, El-Nagger AK . 1994 Cancer Res. 54: 5675–5682
Resnitzky D, Reed SI . 1995 Mol. Cell. Biol. 15: 3463–3469
Rice DH . 1999 Otolaryngol Clin. North Am. 32: 875–886
Samuelson LC . 1996 Annu. Rev. Physiol. 58: 209–229
Schulze A, Zerfass K, Spitkovsky D, Henglein B, Jansen-Durr P . 1994 Oncogene 9: 3475–3482
Sherr CJ . 1996 Science 274: 1672–1677
Shih C, Padhy LC, Murray M, Weinberg RA . 1981 Nature 290: 261–264
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . 1987 Science 235: 177–182
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MP . 1989 Science 244: 707–712
Stal O, Sullivan S, Sun XF, Wingren S, Nordenskjold B . 1994 Cytometry 16: 160–168
Tonin PN . 2000 Semin. Surg. Oncol. 18: 281–286
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y . 1996 Mol. Cell. Biol. 16: 5276–5287
Varley JM, Evans DG, Birch JM . 1997 Br. J. Cancer 76: 1–14
Vogelstein B, Kinzler KW . 1992 Cell 70: 523–526
Webster MA, Muller WJ . 1994 Semin. Cancer Biol. 5: 69–76
Yin Y, Solomon G, Deng C, Barrett JC . 1999 Mol. Carcinog. 24: 15–24
Acknowledgements
We would like to thank D Shanmugarajah for technical assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brodie, S., Xu, X., Li, C. et al. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis. Oncogene 20, 1445–1454 (2001). https://doi.org/10.1038/sj.onc.1204222
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204222
Keywords
This article is cited by
-
Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53
Oncogene (2010)
-
P53 levels determine outcome during β-catenin tumor initiation and metastasis in the mammary gland and male germ cells
Oncogene (2006)
-
Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice
Oncogene (2003)
-
Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice
Oncogene (2001)